Should You Buy, Hold or Sell Tempus AI Stock Heading Into 2026?

Core Insights - Tempus AI's strategic focus for 2026 is on expanding its AI-driven precision medicine platform, scaling the diagnostics business, enhancing data and AI capabilities, and strengthening relationships with healthcare providers and pharmaceutical companies, supported by a commercial pipeline with a total contract value exceeding $1.1 billion [2] Financial Performance - In 2025, Tempus reported total revenues of $1.3 billion, an increase of 83.4% year over year, with the Diagnostics segment generating $955.4 million, reflecting 111.5% year-over-year growth, driven by strong Oncology and Hereditary testing volumes [3][8] - The Data and Applications segment also saw significant growth, generating $316.4 million in revenues, up 30.9% year over year, attributed to strong momentum in the Insights data licensing business [3] Market Position and Competitors - Tempus peers, such as Inspire Medical Systems and 10x Genomics, are expected to maintain growth momentum, with Inspire benefiting from increased adoption of sleep apnea therapy devices and 10x advancing through demand for single-cell and spatial genomics technologies [4] Stock Performance - Over the past year, Tempus shares increased by 15.7%, contrasting with a 25.2% decline in the Zacks Medical Info Systems industry, while peers like Inspire Medical Systems saw a 64.9% drop, and 10x Genomics posted a gain of 96.5% [5] Growth Initiatives - Tempus anticipates strong growth in its oncology diagnostics segment, expecting a 30% growth rate driven by the increasing adoption of genomic sequencing in cancer care, supported by a comprehensive test portfolio [6][9] - The company is also focusing on scaling the Minimal Residual Disease (MRD) testing opportunity, which has shown a 56% quarter-over-quarter volume growth, with plans for gradual commercialization and reimbursement coverage [10][11] Clinical Applications and Software Development - Beyond diagnostics, Tempus is developing clinical applications and healthcare software, including AI-powered tools like TIME and Next, aimed at enhancing patient matching and care pathway intelligence, which will create new revenue opportunities and strengthen its data ecosystem [12] Future Outlook - According to the Zacks Consensus Estimate, Tempus is expected to see a 25.4% improvement in revenues for 2026, although earnings per share are projected to remain negative but improve by 39.3% over 2025 [13]